Patient characteristics
| . | All (n = 113) . | Patients evaluable for PET analysis with visual criteria (n = 102) . | Patients evaluable for PET analysis with visual and ΔSUVmax criteria (n = 85) . |
|---|---|---|---|
| Age, median (range), y | 46 (18-59) | 45 (18-59) | 46 (19-59) |
| Sex, ratio of male to female | 1.4 | 1.3 | 1.1 |
| Ann Arbor stage | |||
| I-II, n (%) | 4 (4) | 4 (4) | 3 (4) |
| III-IV, n (%) | 109 (96) | 98 (96) | 82 (96) |
| LDH | |||
| ≤ Normal, n (%) | 8 (7) | 7 (7) | 7 (8) |
| > Normal, n (%) | 105 (93) | 95 (93) | 78 (92) |
| No. of extranodal sites | |||
| ≤ 1, n (%) | 37 (33) | 28 (34) | 28 (33) |
| > 1, n (%) | 76 (67) | 57 (68) | 57 (67) |
| ECOG | |||
| < 2, n (%) | 85 (76) | 78 (77) | 64 (76) |
| ≥ 2, n (%) | 27 (24) | 23 (23) | 20 (24) |
| Bulky disease (> 10 cm) | |||
| Yes, n (%) | 22 (19) | 21 (21) | 15 (18) |
| No, n (%) | 91 (81) | 81 (79) | 70 (82) |
| Bone marrow involvement | |||
| Involved, n (%) | 25 (22) | 22 (22) | 21 (25) |
| Not involved, n (%) | 83 (73) | 76 (75) | 60 (71) |
| Unspecified, n (%) | 5 (5) | 4 (4) | 4 (5) |
| Age-adjusted IPI | |||
| 1, n (%) | 5 (4) | 5 (5) | 4 (5) |
| 2, n (%) | 87 (78) | 79 (78) | 66 (79) |
| 3, n (%) | 20 (18) | 17 (17) | 14 (17) |
| Subtotal 0-1, n (%) | 5 (4) | 5 (5) | 4 (5) |
| Subtotal 2-3, n (%) | 107 (96) | 96 (95) | 80 (95) |
| Lymphoma subtype (pathology review), n (%) | 82 (73) | 73 (72) | 62 (73) |
| Diffuse large B-cell lymphoma (%) | 75 | 74 | 73 |
| T cell–rich B-cell lymphoma (%) | 4 | 5 | 5 |
| Primary mediastinal B-cell lymphoma (%) | 16 | 16 | 16 |
| Unclassifiable (%) | 2 | 3 | 3 |
| Follicular lymphoma (%) | 1 | 1 | 2 |
| Chemotherapy regimen | |||
| R-ACVBP, n (%) | 58 (51) | 50 (49) | 46 (54) |
| R-CHOP14, n (%) | 55 (49) | 52 (51) | 39 (46) |
| . | All (n = 113) . | Patients evaluable for PET analysis with visual criteria (n = 102) . | Patients evaluable for PET analysis with visual and ΔSUVmax criteria (n = 85) . |
|---|---|---|---|
| Age, median (range), y | 46 (18-59) | 45 (18-59) | 46 (19-59) |
| Sex, ratio of male to female | 1.4 | 1.3 | 1.1 |
| Ann Arbor stage | |||
| I-II, n (%) | 4 (4) | 4 (4) | 3 (4) |
| III-IV, n (%) | 109 (96) | 98 (96) | 82 (96) |
| LDH | |||
| ≤ Normal, n (%) | 8 (7) | 7 (7) | 7 (8) |
| > Normal, n (%) | 105 (93) | 95 (93) | 78 (92) |
| No. of extranodal sites | |||
| ≤ 1, n (%) | 37 (33) | 28 (34) | 28 (33) |
| > 1, n (%) | 76 (67) | 57 (68) | 57 (67) |
| ECOG | |||
| < 2, n (%) | 85 (76) | 78 (77) | 64 (76) |
| ≥ 2, n (%) | 27 (24) | 23 (23) | 20 (24) |
| Bulky disease (> 10 cm) | |||
| Yes, n (%) | 22 (19) | 21 (21) | 15 (18) |
| No, n (%) | 91 (81) | 81 (79) | 70 (82) |
| Bone marrow involvement | |||
| Involved, n (%) | 25 (22) | 22 (22) | 21 (25) |
| Not involved, n (%) | 83 (73) | 76 (75) | 60 (71) |
| Unspecified, n (%) | 5 (5) | 4 (4) | 4 (5) |
| Age-adjusted IPI | |||
| 1, n (%) | 5 (4) | 5 (5) | 4 (5) |
| 2, n (%) | 87 (78) | 79 (78) | 66 (79) |
| 3, n (%) | 20 (18) | 17 (17) | 14 (17) |
| Subtotal 0-1, n (%) | 5 (4) | 5 (5) | 4 (5) |
| Subtotal 2-3, n (%) | 107 (96) | 96 (95) | 80 (95) |
| Lymphoma subtype (pathology review), n (%) | 82 (73) | 73 (72) | 62 (73) |
| Diffuse large B-cell lymphoma (%) | 75 | 74 | 73 |
| T cell–rich B-cell lymphoma (%) | 4 | 5 | 5 |
| Primary mediastinal B-cell lymphoma (%) | 16 | 16 | 16 |
| Unclassifiable (%) | 2 | 3 | 3 |
| Follicular lymphoma (%) | 1 | 1 | 2 |
| Chemotherapy regimen | |||
| R-ACVBP, n (%) | 58 (51) | 50 (49) | 46 (54) |
| R-CHOP14, n (%) | 55 (49) | 52 (51) | 39 (46) |
LDH indicates lactate dehydrogenase; and ECOG, Eastern Cooperative Oncology Group.